By Amélie Boulais, Vaccine Platform Marketing Manager, and Piergiuseppe Nestola, Global Vaccine Technology Consultant
A typical vaccine takes around 10 to 12 years to reach the market, giving developers ample time to consider strategies for mass manufacture. A key question: “Where should we base production?”
A company may plan to build a dedicated manufacturing facility in anticipation of a potential blockbuster (a risky approach – the vaccine could fail in phase III), or may decide to launch the vaccine out of the pilot facility.
Some vaccine manufacturers are now considering the use of flexible facilities that can accommodate the manufacturing of different vaccine types, depending on the demand, which is a challenge given the variability of current legacy vaccine processes.
Learn more about recommendations on how to prepare for the rapid set-up of commercial vaccine manufacturing.